Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: A propensity score–matched analysis Journal Article
| Authors: | Driessen, J.; de Wit, F.; Herrera, A. F.; Zinzani, P. L.; LaCasce, A. S.; Cole, P. D.; Moskowitz, C. H.; García-Sanz, R.; Fuchs, M.; Müller, H.; Borchmann, P.; Santoro, A.; Schöder, H.; Zijlstra, J. M.; Hutten, B. A.; Moskowitz, A. J.; Kersten, M. J. |
| Article Title: | Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: A propensity score–matched analysis |
| Abstract: | Several single-arm studies have explored the inclusion of brentuximab vedotin (BV) in salvage chemotherapy followed by autologous stem cell transplantation (ASCT) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, no head-to-head comparisons with standard salvage chemotherapy have been performed. This study presents a propensity score–matched analysis encompassing individual patient data from 10 clinical trials to evaluate the impact of BV in transplant-eligible patients with R/R cHL. We included 768 patients, of whom 386 were treated with BV with or without chemotherapy (BV cohort), whereas 382 received chemotherapy alone (chemotherapy cohort). Propensity score matching resulted in balanced cohorts of 240 patients each. No significant differences were observed in pre-ASCT complete metabolic response (CMR) rates (P = .69) or progression free survival (PFS; P = .14) between the BV and chemotherapy cohorts. However, in the BV vs chemotherapy cohort, patients with relapsed disease had a significantly better 3-year PFS of 80% vs 70%, respectively (P = .02), whereas there was no difference for patients with primary refractory disease (56% vs 62%, respectively; P = .67). Patients with stage IV disease achieved a significantly better 3-year PFS in the BV cohort (P = .015). Post-ASCT PFS was comparable for patients achieving a CMR after BV monotherapy and those receiving BV followed by sequential chemotherapy (P = .24). Although 3-year overall survival was higher in the BV cohort (92% vs 80%, respectively; P < .001), this is likely attributed to the use of other novel therapies in later lines for patients experiencing progression, given that studies in the BV cohort were conducted more recently. In conclusion, BV with or without salvage chemotherapy appears to enhance PFS in patients with relapsed disease but not in those with primary refractory cHL. © 2024 by The American Society of Hematology. |
| Keywords: | adult; cancer chemotherapy; aged; middle aged; overall survival; prednisone; cancer recurrence; salvage therapy; doxorubicin; drug efficacy; gemcitabine; radiation dose; positron emission tomography; carboplatin; cancer immunotherapy; progression free survival; multiple myeloma; etoposide; cyclophosphamide; vincristine; autologous stem cell transplantation; ifosfamide; procarbazine; acute lymphoblastic leukemia; hodgkin disease; remission; bleomycin; follicular lymphoma; chemoradiotherapy; non-hodgkin lymphoma; classical hodgkin lymphoma; non small cell lung cancer; phase 2 clinical trial (topic); phase 3 clinical trial (topic); autotransplantation; acute myeloid leukemia; propensity score; diffuse large b cell lymphoma; brentuximab vedotin; peritoneal dialysis; human; male; female; article; positron emission tomography-computed tomography; vinorelbine tartrate |
| Journal Title: | Blood Advances |
| Volume: | 8 |
| Issue: | 11 |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-06-11 |
| Start Page: | 2740 |
| End Page: | 2752 |
| Language: | English |
| DOI: | 10.1182/bloodadvances.2023012145 |
| PUBMED: | 38502227 |
| PROVIDER: | scopus |
| PMCID: | PMC11170165 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work